Daccó L, Intrieri L
Clin Ther. 1986;8(2):170-4.
Forty inpatient men and women, between 50 and 80 years of age, with nocturia due to bladder instability, resorption of postural edema, or senile involution were admitted to a clinical trial designed to test the possibility of reducing or eliminating nocturnal voidings by means of a single evening dose of rociverine or flavoxate. This six-day crossover trial was divided into three periods of two days each: pretrial, treatment with one drug, and treatment with the other drug. Either 20 mg of rociverine or 200 mg of flavoxate was given at 8 PM in randomized sequence. For each night of the study, the following data were recorded: interval between drug administration and first voiding, volume of first voiding, total volume of nocturnal urine, total volume of nocturnal urine plus volume of urine passed on waking, and total number of nocturnal voidings. The outcome was a significant reduction of the number of nocturnal voidings together with a marked lengthening of the interval between drug administration and first voiding, with no noteworthy differences between the two drugs. Considering the efficacy of rociverine and, even more important, the excellent tolerance of elderly patients to the drug, further study of rociverine in nocturia and in urinary incontinence seems indicated.
40名年龄在50至80岁之间、因膀胱不稳定、体位性水肿吸收或老年性萎缩而患有夜尿症的住院男女患者被纳入一项临床试验，该试验旨在测试通过单次晚间服用罗西维林或黄酮哌酯来减少或消除夜间排尿的可能性。这项为期六天的交叉试验分为三个为期两天的阶段：试验前、用一种药物治疗以及用另一种药物治疗。在晚上8点以随机顺序给予20毫克罗西维林或200毫克黄酮哌酯。在研究的每个夜晚，记录以下数据：给药至首次排尿的间隔时间、首次排尿量、夜间尿量、夜间尿量加上醒来时排尿量的总和以及夜间排尿总数。结果是夜间排尿次数显著减少，同时给药至首次排尿的间隔时间明显延长，两种药物之间无显著差异。考虑到罗西维林的疗效，更重要的是老年患者对该药物的良好耐受性，似乎有必要对罗西维林在夜尿症和尿失禁方面进行进一步研究。
